PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™…
<!-- Name:DistributionId Value:8797519 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
clinical development
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast…
<!-- Name:DistributionId Value:8740966 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Artificial Intelligence (AI) in Drug Discovery Market Worth $8.95 Billion by 2030…
Redding, California, Jan. 26, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, 'Artificial Intelligence in Drug Discovery Market by Offering (Software,…
VPM oversees clinical trial and translational project management – Positive Phase I…
HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service provider supporting small and medium pharma…
dMed | Clinipace announce corporate name change to Caidya
SHANGHAI and MORRISVILLE, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- dMed |Clinipace, the established contract research organization serving global innovators such as biotechs, announced…
Insilico Medicine Appoints Sujata Rao, M.D., as Senior Vice President to Oversee…
New York, July 19, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, has appointed Dr. Sujata Rao as…
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal…
GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the…
Lui Franciosi To Monitor the Safety and Efficacy of Nebulized Heparin for the…
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi will be monitoring the safety and efficacy of nebulized heparin for the treatment of SARS-CoV-2, i.e.,…
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the…
GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety…